Dr Gerald Batist speaks to ecancer at the WIN 2019 Symposium in Paris about a precision medicine approach to therapeutic resistance using KEAP1 somatic mutations to target patients to correct protein-protein interaction disrupted by this mutation.

He explains that often cancer patients will relapse and second and third lines of therapy become unsuccessful due to resistance.

Dr Batist explains that using molecular modelling they have found a drug that can lower resistance and sensitise tumours to chemotherapies and immunotherapies.